ASH 2023 | Patient characteristics and outcomes of alloSCT for BPDCN
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a retrospective, single-center analysis which evaluated the outcomes of 31 patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with allogeneic stem cell transplantation (alloSCT). Dr Qazilbash highlights that patients undergoing alloSCT in first remission had significantly better outcomes, but generally, the safety and efficacy of alloSCT in these patients are favorable. Further prospective studies are warranted to better understand the role of alloSCT in BPDCN. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: Bioline
Research Funding: Amgen, Janssen, Angiocrine, NexImmune
